Literature DB >> 19656660

Differential down-regulation of COX-2 and MMP-13 in human skin fibroblasts by glucosamine-hydrochloride.

Hua Hong1, Yu-Kyoung Park, Mi-Sun Choi, Nam-Hee Ryu, Dae-Kyu Song, Seong-Il Suh, Ki-Young Nam, Gy-Young Park, Byeong-Churl Jang.   

Abstract

BACKGROUND: Evidence suggests anti-inflammatory effects of glucosamine (GS) on inflammatory diseases. COX-2 is an enzyme to produce prostaglandins. MMPs are the family of matrix metalloproteinases degradable of ECM. Excess expression of COX-2 or MMPs involves in skin inflammation.
OBJECTIVE: We evaluated whether GS-HCl modulates expression of COX-2 and/or MMPs by IL-1beta or PMA in human skin fibroblasts (HSF) or keratinocytes (HaCaT).
METHODS: HSF or HaCaT cells were exposed to IL-1beta or PMA without or with GS-HCl. COX-2 or MMPs protein and mRNA expression, respectively, were analyzed by Western blot and RT-PCR. MTS assay was utilized to assess the cytotoxicity of GS-HCl on HSF cells.
RESULTS: In HSF cells, IL-1beta treatment induced COX-2 and MMP-13 expressions in association with activation of ERKs, p38 MAPK, JNKs, and NF-kappaB. PMA treatment also induced COX-2 and MMP-13 expressions in association with p38 MAPK activation. Of interest, treatment with GS-HCl (10mM) led to blockage of p38 MAPK activation, accumulation of 66kDa COX-2 protein variant (without affecting COX-2 mRNA expression), and transcriptional down-regulation of MMP-13 in the IL-1beta- or PMA-treated HSF cells. Distinctly, pharmacological inhibition of p38 MAPK with SB203580 was associated with transcriptional down-regulation of COX-2 and MMP-13 in the IL-1beta- or PMA-treated HSF cells. In addition, the GS-HCl-mediated COX-2 protein modification was observed in both endogenous and PMA-induced COX-2 in HaCaT cells.
CONCLUSIONS: GS-HCl differentially down-regulates COX-2 and MMP-13 expression in the IL-1beta- or PMA-treated human skin fibroblasts via the p38 MAPK-independent COX-2 translational inhibition and the p38 MAPK-dependent MMP-13 transcriptional suppression, respectively.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19656660     DOI: 10.1016/j.jdermsci.2009.06.017

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  10 in total

1.  Use of glucosamine and chondroitin supplements in relation to risk of colorectal cancer: Results from the Nurses' Health Study and Health Professionals follow-up study.

Authors:  Elizabeth D Kantor; Xuehong Zhang; Kana Wu; Lisa B Signorello; Andrew T Chan; Charles S Fuchs; Edward L Giovannucci
Journal:  Int J Cancer       Date:  2016-07-18       Impact factor: 7.396

Review 2.  Chondroitin and glucosamine in the management of osteoarthritis: an update.

Authors:  Yves Henrotin; Cécile Lambert
Journal:  Curr Rheumatol Rep       Date:  2013-10       Impact factor: 4.592

3.  Glucosamine Use and Risk of Colorectal Cancer: Results from UK Biobank.

Authors:  Elizabeth D Kantor; Kelli O'Connell; Peter S Liang; Sandi L Navarro; Edward L Giovannucci; Mengmeng Du
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-03-01       Impact factor: 4.090

4.  Down-regulation of IL-6, IL-8, TNF-α and IL-1β by glucosamine in HaCaT cells, but not in the presence of TNF-α

Authors:  Kun Park; Ji-Hye Lee; Ho-Chan Cho; Sun-Young Cho; Jae-We Cho
Journal:  Oncol Lett       Date:  2010-03-01       Impact factor: 2.967

5.  Glucosamine use and risk of colorectal cancer: results from the Cancer Prevention Study II Nutrition Cohort.

Authors:  Elizabeth D Kantor; Christina C Newton; Edward L Giovannucci; Marjorie L McCullough; Peter T Campbell; Eric J Jacobs
Journal:  Cancer Causes Control       Date:  2018-02-06       Impact factor: 2.506

6.  Glucosamine and Chondroitin Use in Relation to C-Reactive Protein Concentration: Results by Supplement Form, Formulation, and Dose.

Authors:  Elizabeth D Kantor; Kelli O'Connell; Mengmeng Du; Chao Cao; Xuehong Zhang; Dong Hoon Lee; Yin Cao; Edward L Giovannucci
Journal:  J Altern Complement Med       Date:  2020-12-07       Impact factor: 2.579

7.  Isatis tinctoria L.-derived Petroleum Ether Extract Mediates Anti-inflammatory Effects via Inhibition of Interleukin-6, Interleukin-33 and Mast Cell Degranulation.

Authors:  Tobias Lotts; Kathrin Kabrodt; Johanna Hummel; Dorit Binder; Ingo Schellenberg; Sonja Ständer; Konstantin Agelopoulos
Journal:  Acta Derm Venereol       Date:  2020-05-11       Impact factor: 3.875

8.  Polygonum multiflorum Thunb. Extract Stimulates Melanogenesis by Induction of COX2 Expression through the Activation of p38 MAPK in B16F10 Mouse Melanoma Cells.

Authors:  Donghee Kim; Hyo-Jin Kim; Hee-Sook Jun
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-25       Impact factor: 2.629

9.  Defective Induction of COX-2 Expression by Psoriatic Fibroblasts Promotes Pro-inflammatory Activation of Macrophages.

Authors:  Jorge Arasa; María Carmen Terencio; Rosa María Andrés; Asunción Marín-Castejón; Francisca Valcuende-Cavero; Miguel Payá; María Carmen Montesinos
Journal:  Front Immunol       Date:  2019-03-20       Impact factor: 7.561

10.  Chondrogenic Potential of Pellet Culture Compared to High-Density Culture on a Bacterial Cellulose Hydrogel.

Authors:  Nele Pascale Grigull; Julia Isabelle Redeker; Bärbel Schmitt; Maximilian Michael Saller; Veronika Schönitzer; Susanne Mayer-Wagner
Journal:  Int J Mol Sci       Date:  2020-04-16       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.